In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
The Overview: December 2025
Friends: This has been a pivotal year for Ovarian Cancer Research Alliance (OCRA), defined by powerful forward momentum—from launching the Global Ovarian Cancer Research Consortium to preparing the Community Accelerated Research Exchange for its debut, expanding essential support and education programs, and establishing our new Center for Public Policy. These developments, along with the progress highlighted below, signal a turning … Continued
OCRA’s Advocate’s Corner: December 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance As 2025 ends, we’re reflecting on a year marked by growth, resilience, and meaningful impact. In a complex policy environment, one thing remained constant: the dedication of OCRA’s advocates to advancing policies that strengthen care, access, and support for people impacted by ovarian and gynecologic … Continued
OCRA Hero Climbs Empire State Building to Support Ovarian Cancer Research
First-Time Participant Tackles 1,576 Steps to Honor Family and Support OCRA Earlier this year, Crystal Merope Jeffs took her support for the ovarian and gynecologic cancer community to new heights—literally—when she entered the lottery for the Empire State Building Run-Up. I decided to do something a little wild—to run up the Empire State Building. All … Continued